Preservative-Free Triamcinolone Acetonide Suspension Developed for Intravitreal Injection

Bitter, Christoph; Suter, Katja; Figueiredo, Verena; Pruente, Christian; Hatz, Katja; Surber, Christian

doi:10.1089/jop.2007.0043

Cited by 13 publications

(4 citation statements)

References 53 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6 For intravitreal TA application, possible retinal toxicity from the preservative benzyl alcohol has been a concern, which stimulated the various decanting techniques 35 and the development of preservative-free TA formulations (Triesence; Alcon Laboratories, Inc.; Trivaris, Allergan, Inc). Thus far, toxicity studies of commercially preserved intravitreal TA have been performed in various settings and the results have been conflicting.…”

Section: Discussionmentioning

confidence: 99%

Further Characterization of Ocular Safety Profile of Commercially Available Preserved and Preservative-Free Triamcinolone Acetonide

Chen

Hou

et al. 2012

Retina

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Further Characterization of Ocular Safety Profile of Commercially Available Preserved and Preservative-Free Triamcinolone Acetonide

Chen

Hou

et al. 2012

Retina

View full text Add to dashboard Cite

show abstract

“…The evidence of retinal toxicity secondary to the compounds in preserved TA formulations such as benzyl alcohol led to an urgent need to find alternative compounds and to create preservative-free formulations. In 2006, Bitter and colleagues developed a simple, reproducible method to produce stable, preservative-free TA (PF-TA) suspensions that can be successfully applied intravitreally [20]. Subsequently, Kim et al evaluated the safety and pharmacokinetics of the preservative-free formulation of TA in intravitreal injections in rabbits.…”

Section: Preserved and Preservative-free Triamcinolone Acetonide Form...mentioning

confidence: 99%

“…In addition, several complications have been related to this route of administration, such as intraocular infection, retinal detachment, and lens injury [19]. Preservative-containing TA formulations have been shown to produce retinal toxicity after their administration, leading to the development of preservative-free TA formulations [20]. Antiangiogenic drugs have displaced the use of steroids for vitreoretinal diseases and have become the gold standard treatment for these pathologies [21].…”

Section: Introductionmentioning

confidence: 99%

The Evolution of Triamcinolone Acetonide Therapeutic Use in Retinal Diseases: From Off-Label Intravitreal Injection to Advanced Nano-Drug Delivery Systems

Aceves-Franco,

Sanchez-Aguilar,

Barragan-Arias

et al. 2023

Biomedicines

View full text Add to dashboard Cite

Ophthalmic drug delivery to the posterior segment of the eye has been challenging due to the complex ocular anatomy. Intravitreal injection of drugs was introduced to deliver therapeutic doses in the posterior segment. Different posterior segment diseases including age-related macular degeneration, diabetic macular edema, retinal vein occlusions, uveitis, and cystoid macular edema, among others, have been historically treated with intravitreal corticosteroids injections, and more recently with intravitreal corticosteroids drug implants. Triamcinolone acetonide (TA) is the most frequently used intraocular synthetic corticosteroid. Using nanoparticle-based TA delivery systems has been proposed as an alternative to intravitreal injections in the treatment of posterior segment diseases. From these novel delivery systems, topical liposomes have been the most promising strategy. This review is oriented to exhibit triamcinolone acetonide drug evolution and its results in treating posterior segment diseases using diverse delivery platforms.

show abstract

“…[5][6][7]27 Triamcinolone acetonide was prepared preservative-free through a sedimentation technique previously described. 28,29 Each patient gave writ-ten informed consent after the experimental nature, risks, and benefits of all of the therapy options had been explained. The study followed the guidelines of the Declaration of Helsinki.…”

Section: Subjects and Treatmentsmentioning

confidence: 99%

Early Effects of Intravitreal Triamcinolone Acetonide on Inflammation and Proliferation in Human Choroidal Neovascularization

Tatar

Adam²,

Shinoda³

et al. 2009

Arch Ophthalmol

View full text Add to dashboard Cite

To evaluate the early effects of triamcinolone acetonide (TA) on inflammation, proliferation, and vascular endothelial growth factor (VEGF) in human choroidal neovascularization (CNV). Methods: Retrospective review of an interventional case series of 29 patients who underwent macular translocation. Fourteen CNV membranes without previous therapy (control CNV group) and 4 CNV membranes excised 3 days after photodynamic therapy (PDT CNV group) comprised the control groups. Eleven patients were treated with intravitreal TA (TA CNV group; n = 5) or PDT and TA combined (PDTϩTA CNV group; n = 6) 3 to 9 days preoperatively. The CNV membranes were stained for cytokeratin 18, CD34, VEGF, intercellular adhesion molecule-1 (ICAM-1), E-selectin, CD68, CD45, Ki-67, and Thy-1. Results: Treatment with TA and PDTϩTA resulted in increased immunostaining of ICAM-1 in endothelial cells and the stroma and a higher percentage of Thy-1 expression than controls. The density of macrophages was significantly increased in PDTϩTA CNV membranes. Leukocyte density and proliferative activity were lower in TA and PDTϩTA CNV membranes. The total VEGF score was significantly increased in TA and PDTϩTA CNV membranes compared with the control CNV membranes. Evidence of VEGF in the retinal pigment epithelium of PDTϩTA CNV membranes was stronger than in control CNV membranes. Conclusions: Triamcinolone acetonide has no inhibitory effect on macrophage infiltration or ICAM-1, Thy-1, or VEGF expression in CNV membranes in the early term. The clinical benefits of TA are probably not based on pure antiinflammatory or VEGF-suppressing mechanisms.

show abstract

Preservative-Free Triamcinolone Acetonide Suspension Developed for Intravitreal Injection

Abstract: We developed a simple, reproducible method to compound stable, completely preservative-free TACA suspensions with a reasonable shelf-life, which enables to study the effect of intravitreal TACA--not biased by varying doses and toxic compounds or their residues.

Cited by 13 publications

References 53 publications

Further Characterization of Ocular Safety Profile of Commercially Available Preserved and Preservative-Free Triamcinolone Acetonide

Further Characterization of Ocular Safety Profile of Commercially Available Preserved and Preservative-Free Triamcinolone Acetonide

The Evolution of Triamcinolone Acetonide Therapeutic Use in Retinal Diseases: From Off-Label Intravitreal Injection to Advanced Nano-Drug Delivery Systems

Early Effects of Intravitreal Triamcinolone Acetonide on Inflammation and Proliferation in Human Choroidal Neovascularization

Contact Info

Product

Resources

About